The development of ICI therapy, such as those targeting programmed cell death ligand 1 (PD-L1) and anti-programmed death-1 (anti-PD-1), has significantly improved the treatment outcomes for patients with MCC [4,16,23]. The gene discussed is CD274; the disease is Merkel cell skin cancer.